SavedAdd your journal

Journals / Journal of Neurological Sciences (Turkish) / 2009 / Cilt: 26 - Sayı: 2

Multipl skleroz hastalarında interferon-β tedavisi: Hasta yaşı ile tedaviye yanıtlılık ilişkisi

Interferon-β theraphy in multiple sclerosis patients: Is response age dependent?

Murat TERZİ
Ömer Faruk AYDIN
Musa Kazım ONAR
Aslı KURNE
Rana KARBUDAK
Pages
131–138
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In responder patients, female to male ratio was higher for older age onset patients (12/13 vs 36/60) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The onset of Multiple sclerosis (MS) is usually between 20 and 40 years and in those patients, β -interferons reduce relapse frequency in a rate of 30%.
📊
Key Findings & Data:The purpose of this study was to compare the therapeutical response to IFNβ in young versus older MS patients.Multiple sclerosis patients with onset of symptoms older 40 were described as older age-onset MS (OAOMS) and the patients with onset of symptoms lower than 20 years were described as a young-onset MS (YOMS).
💡
Conclusion & Impact:In responder patients, female to male ratio was higher for older age onset patients (12/13 vs 36/60) (p
🔬Design:Review & Systematic Survey
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

The onset of Multiple sclerosis (MS) is usually between 20 and 40 years and in those patients, β -interferons reduce relapse frequency in a rate of 30%. The purpose of this study was to compare the therapeutical response to IFNβ in young versus older MS patients.Multiple sclerosis patients with onset of symptoms older 40 were described as older age-onset MS (OAOMS) and the patients with onset of symptoms lower than 20 years were described as a young-onset MS (YOMS). Eighty-five YOMS patients and 22 OAOMS patients were enrolled from 1997 to 2007 and medical records for each patient were reviewed. Individuals with relapse rates of more than 1/year, who fail in reducing their attack rates and/or deterioration of disability, were described as evidence for lack of therapeutic response.In the YOMS group, 70,6% of patients were responder. This ratio were 59% in OAOMS group with no statistically difference. Female to male ratio was 2.15:1 in young patients and 3.4:1 in older patients. Older MS patients had a higher EDSS score at initiation of IFNβ therapy. In responder patients, female to male ratio was higher for older age onset patients (12/13 vs 36/60) (p

Özet

Multipl Skleroz (MS), genellikle 20-40 yaşları arasında başlar. Hastaların %30’unda, β-interferon tedavisi ile relaps sıklığı azalır. Bu çalışmanın amacı, genç ve yaşlı MS hastalarında IFNβ yanıtlılığını karşılaştırmaktır.Semptomları 40 yaşından sonra başlayan hastalar geç-başlangıçlı MS (GBMS), 20 yaşından önce başlayan hastalar ise erken-başlangıçlı MS (EBMS) olarak tanımlanmıştır. 1997-2007 yılları arasında izlenen, erken-başlangıçlı 85 MS ve geç-başlangıçlı 22 MS hastasının tıbbi kayıtları incelendi. Atak sayısında azalma olmayan ve/veya özürlülüğü artan, atak sayısı yılda 1’den fazla olan hastalar tedaviye yanıtsız olarak değerlendirildi.Erken-başlangıçlı MS grubunda, hastaların %70,6’sı tedaviye yanıtlı bulundu. Bu oran, GBMS hastalarında %59 olup iki grup arasında tedaviye yanıtlılık açısından fark yoktu. IFNβ tedavisi başlangıcında, GBMS hastalarında EDSS puanları daha yüksekti. Kadın:Erkek oranı, EBMS grubunda 2,15:1 iken GBMS grubunda 3,4:1 bulundu. Tedaviye yanıtlı hastalarda, Kadın:Erkek oranı GBMS grubunda anlamlı olarak daha yüksekti (GBMS=12/13, EBMS=36/60, p

🔖

Cite This Article

TERZİ, M., AYDIN, Ö. F., ONAR, M. K., KURNE, A., KARBUDAK, R. (2022). Multipl skleroz hastalarında interferon-β tedavisi: Hasta yaşı ile tedaviye yanıtlılık ilişkisi. Journal of Neurological Sciences (Turkish), Cilt: 26 - Sayı: 2, 131–138. https://ajindex.com/articles/565506

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281–300
  2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770–782
  3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112 (Pt 1): 133-46
  4. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116: 117–134
  5. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58(3): 300-6
  6. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51(3): 765-72
  7. Noseworthy J, Paty D, Wonnacott T, et al. Multiple sclerosis after age 50. Neurology 1983; 33:1537–1544
  8. Delalande S, De Seze J, Ferriby D, et al. Late onset multiple sclerosis. Rev Neurol (Paris) 2002; 158(11):1082–1087
  9. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study
  10. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114 (Pt 2):1045-56
  11. Visscher BR, Liu KS, Clark VA, et al. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand 1984; 70(5): 321-8
  12. Runmarker B, Andersson C, Odén A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994; 241(10): 597-604
  13. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36: S6-S11
  14. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58(3): 300-6
  15. Trojano M, Liguori M, Bosco Zimatore G, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002; 51(4): 475-80
  16. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001; 189:13–21
  17. Azzimondi G, Stracciari A, Rinaldi R, e